Highlightll will receive $10M up front in cash, $10M in BHVN equity & ~$950M in development & commercial milestones along with royalty. Both companies will coordinate the clinical development across global regions
Biohaven obtains global rights (Ex-China) for the development of BHV-8000, a highly selective, brain-penetrant, dual TYK2/JAK1 inhibitor to treat brain disorders
Biohaven continues to advance BHV-8000 (previously TLL-041) licensed from Highlightll into a P-I study in 2023. In comparison to less selective or non-selective JAK inhibitors, BHV-8000 has been shown to have high selectivity over JAK2, JAK3, & other kinases potentially providing improved safety. In preclinical models, mechanistic PoC for BHV-8000 has been established
Ref: PR Newswire | Image: Biohaven
Related News:- Biohaven Entered into an Exclusive License and Research Agreement with KU Leuven to Develop and Commercialize BHV-2100 for Chronic Pain Disorders
